Brief: First Wave Biopharma Announces Completion Of Business Combination With Immunogenx
14/03/2024 11:44
March 14 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA ANNOUNCES COMPLETION OF BUSINESS
COMBINATION WITH IMMUNOGENX, ADDING PHASE 3-READY LATIGLUTENASE
TO ITS LATE-STAGE GI-FOCUSED CLINICAL PIPELINE
* INTENDS TO LICENSE COMMERCIAL RIGHTS TO LATIGLUTENASE IN
UNITED
STATES AND CANADA
Source text for Eikon: ID:nGNX22hjzj
Further company coverage: FWBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement